Literature DB >> 10821405

Cation-exchange high-performance liquid chromatography of recombinant adeno-associated virus type 2.

D Debelak1, J Fisher, S Iuliano, D Sesholtz, D L Sloane, E M Atkinson.   

Abstract

There has been much interest recently in the development of recombinant viruses as vectors for gene therapy applications. We have constructed a recombinant adeno-associated viral (AAV) vector containing the gene encoding CFTR (cystic fibrosis transmembrane chloride regulator). This vector is currently being used in clinical trials as a treatment for cystic fibrosis. In the course of scale-up and process optimization efforts, a variety of analyses have been developed to characterize yield and quality. Although these methods produce quantitative and highly reproducible results, most are very time intensive. For example, a standard bioassay requires a 72-h incubation period followed by an additional day of analysis. Other tests such as UV spectrophotometry are fast, but unable to distinguish between whole virus, free protein, and DNA. Here, we describe an analytical cation-exchange high-performance liquid chromatographic method utilizing a TSKgel SP-NPR strong cation-exchange column. Unlike the bioassay which requires a 96-h wait for information, this method yields data in less than 20 min. In addition to the quick assay turn-around, the material eluting in the single peak was found to be intact, infectious, nuclease resistant AAV particles. This offers a significant advantage over the limited information one gains from UV spectrophotometry. This demonstrates the utility of chromatography for analysis and purification of viral vectors.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10821405     DOI: 10.1016/s0378-4347(00)00100-6

Source DB:  PubMed          Journal:  J Chromatogr B Biomed Sci Appl        ISSN: 1387-2273


  6 in total

Review 1.  Large-scale recombinant adeno-associated virus production.

Authors:  Robert M Kotin
Journal:  Hum Mol Genet       Date:  2011-04-29       Impact factor: 6.150

2.  Addition of six-His-tagged peptide to the C terminus of adeno-associated virus VP3 does not affect viral tropism or production.

Authors:  Huang-Ge Zhang; Jinfu Xie; Igor Dmitriev; Elena Kashentseva; David T Curiel; Hui-Chen Hsu; John D Mountz
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

3.  A pseudo-plaque method for infectious particle assay and clonal isolation of adeno-associated virus.

Authors:  Daniel A J Mitchell; Thomas F Lerch; Joan T Hare; Michael S Chapman
Journal:  J Virol Methods       Date:  2010-08-11       Impact factor: 2.014

4.  Targeted correction of single-base-pair mutations with adeno-associated virus vectors under nonselective conditions.

Authors:  Xiaoming Liu; Ziying Yan; Meihui Luo; Roman Zak; Ziyi Li; Ryan R Driskell; Yumao Huang; Nam Tran; John F Engelhardt
Journal:  J Virol       Date:  2004-04       Impact factor: 5.103

5.  Near-perfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors.

Authors:  N Zeltner; E Kohlbrenner; N Clément; T Weber; R M Linden
Journal:  Gene Ther       Date:  2010-03-25       Impact factor: 5.250

6.  Rapid In-Process Monitoring of Lentiviral Vector Particles by High-Performance Liquid Chromatography.

Authors:  Julia Transfiguracion; Michelle Yen Tran; Stéphane Lanthier; Sonia Tremblay; Nathalie Coulombe; Mauro Acchione; Amine A Kamen
Journal:  Mol Ther Methods Clin Dev       Date:  2020-08-05       Impact factor: 6.698

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.